25 May 2013
Keywords: cladribine, enters, trial, patients, risk, ms, merck
Article | 29 September 2008
Merck Serono, a division of Germany's Merck KGaA, has initiated a Phase III trial to evaluate the therapeutic effects of ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
29 September 2008
22 September 2008
24 May 2013
© 2013 thepharmaletter.com